SCHEDULE: Monopar Therapeutics Buys Back Shares from Tactic Pharma

Monopar Therapeutics is repurchasing 550,229 shares of its common stock from Tactic Pharma LLC at $63.6098 per share, contingent on a concurrent public offering.

Summary

• Tactic Pharma LLC agreed to sell 550,229 shares of Monopar Therapeutics common stock back to the Issuer.
• The sale price is $63.6098 per share, which is the same price as a concurrent public offering by Monopar, less underwriting discounts and commissions.
• The transaction is conditional on the closing of the Offering and is expected to close promptly thereafter.
• Following this transaction, Tactic Pharma LLC, Andrew Mazar, and Thomas O'Halloran will no longer beneficially own more than 5% of Monopar's common stock.
• Chandler Robinson and Michael Brown will continue to beneficially own more than 5% of the common stock, with 7.5% and 5.1% respectively.
• The calculation of beneficial ownership percentages is based on 6,611,661 shares outstanding after the Offering.

Sentiment

Score: 6

Explanation: The repurchase itself is generally positive, but the reduction in stake by a major holder and the reliance on a concurrent offering introduce some neutrality. It's a strategic capital management move rather than a clear indicator of operational performance.

Positives

• Monopar Therapeutics is repurchasing shares, which can be seen as a way to return capital to shareholders or reduce dilution from the concurrent offering.
• The repurchase price is tied to the offering price, suggesting a fair market value for the transaction.

Negatives

• A significant shareholder, Tactic Pharma LLC, is reducing its stake, which could be interpreted negatively by some investors.
• The transaction is contingent on an 'Offering,' implying potential dilution for existing shareholders from that separate event.

Risks

• The share repurchase transaction is conditioned on the closing of a separate 'Offering,' meaning the repurchase might not occur if the Offering fails.
• A lock-up agreement among Tactic Pharma and Gem Pharmaceuticals, LLC, prohibiting sales of distributed Common Stock until December 31, 2025, was waived for this specific transaction but remains in effect for other sales, potentially limiting future liquidity for these parties.

Future Outlook

The transaction for the share repurchase is conditioned on the closing of a separate public offering by Monopar Therapeutics and is expected to close promptly thereafter.

Industry Context

Share repurchases can signal management's belief that the stock is undervalued or can be a way to manage capital structure. In the biotech/pharma industry, such transactions might be less common than in mature industries, often indicating specific strategic capital allocation or a major shareholder's decision to rebalance their portfolio. The tie-in to a concurrent offering suggests a coordinated capital markets strategy.

Comparison to Industry Standards

• NA

Related Party Transactions

• Tactic Pharma LLC, a reporting person, is selling shares back to the Issuer, Monopar Therapeutics. This is a transaction between a significant shareholder and the company.

Stakeholder Impact

• Shareholders: The repurchase could be accretive to earnings per share for remaining shareholders, but the concurrent offering might dilute them. The reduction in a major holder's stake could be viewed differently by various investors.
• Tactic Pharma LLC: Reduces its stake in Monopar Therapeutics, potentially realizing capital.
• Monopar Therapeutics: Reduces its outstanding share count (from the repurchase) and potentially raises capital (from the offering).

Next Steps

• Closing of the Issuer's concurrent public offering.
• Closing of the privately negotiated stock purchase agreement between Tactic Pharma LLC and Monopar Therapeutics.

Key Dates

Recommendation

The filing details a significant share repurchase by Monopar Therapeutics from Tactic Pharma LLC, contingent on a concurrent public offering. While share repurchases can be accretive, the reduction in a major shareholder's stake and the reliance on a separate offering for capital raise suggest a strategic rebalancing rather than a clear signal of strong operational performance or undervaluation. Investors should hold and await further details on the offering and the company's operational results.

Keywords

Monopar Therapeutics, Tactic Pharma, Share Repurchase, SEC Filing, Schedule 13D, Common Stock, Beneficial Ownership, Equity Transaction, Biotechnology, Pharmaceuticals